X

Trial Profile

A clinical study of combined strains of live bacteria in hospitalized COVID-19 patients

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bacteriotherapy-ExeGi Pharma (Primary) ; Antibacterials; Hydroxychloroquine; Tocilizumab
Indications COVID 2019 infections; Diarrhoea; Respiratory insufficiency
Focus Adverse reactions; Therapeutic Use
Sponsors ExeGi Pharma

Most Recent Events

16 Jul 2020 New trial record
13 Jul 2020 According to a ExeGi Pharma media release, this study was conducted in a hospital setting in Rome. Giancarlo Ceccarelli is one of the study investigators.
13 Jul 2020 According to a ExeGi Pharma media release, this study was published in the peer-reviewed journal Frontiers in Medicine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com